跳至主要内容
临床试验/JPRN-C000000239
JPRN-C000000239已完成1 期

A phase I/II study of concurrent chemoradiation with irinotecan hydrochloride(CPT-11) and cisplatin(CDDP) for uterine cervical cancer. (KCOG 0328) - A phase I/II study of concurrent chemoradiation with CPT-11 and CDDP for uterine cervical cancer. (KCOG 0328)

Kansai Clinical Oncology Group (KCOG)0 个研究点目标入组 18 人开始时间: 2005年9月16日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 75years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Severe complications: a) infections, diarrhea (watery), ileus, interstistial pneumonitis, lung fibrosis, b) massive pleural effusion or ascites, c) uncontrollable diabetes mellitus, d) other complications which suffer from progressing study. 2) Co-existence of active other malignancies. 3) The patients with prior radiotherapy whose treatment area of irradiation will be overlaid to ex-treatment area. 4) Pregnant or expected to be pregnant and breast feeding mother. 5) Known severe hypersensitivity to agent. 6) Whom the investigator think unappropriate as a candidate.

研究者

发起方
Kansai Clinical Oncology Group (KCOG)

相似试验